May 30,2007
Sen. Grassley seeks additional information about pricing and marketing of anti-anemia drugs
WASHINGTON --- Sen. Chuck Grassley is asking a leading drug maker to cooperate with his ongoing inquiry into the pricing and marketing of anti-anemia drugs given to kidney and cancer patients and the Food and Drug Administration’s access to data from the drug maker’s studies of such drugs.
The text of the letter Grassley sent today to Johnson & Johnson is below, along with the text of inquiries he made earlier this month and in April of the Food and Drug Administration, Amgen Inc. and the Centers for Medicare and Medicaid Services.
Grassley is Ranking Member of the Senate Committee on Finance.
###
Next Article Previous Article
Recent News
- Wyden and Merkley Call on Oz to Resolve Chaos as States Implement Trumpcare
- Democratic Senators Demand Transparency, Accountability for Massive Rise in National Security Tariffs
- Wyden, Schumer, Warren Sound Alarm Over Trump Weaponization of the IRS Against the Free Speech Rights of Trump Opponents
- Finance Democrats Call for Halt to Unlawful Nomination of March Bell to be Health Care Inspector General
- Wyden, Welch, Cortez Masto Introduce Bill to Block Republicans’ Big Pharma Bailout, Protect Access to Life-Saving Prescription Drugs